Fisher & Paykel’s Long-Term Trajectory Intact

Fisher & Paykel is well positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is priority, followed by targeting treatment of COPD in the homecare segment, and longer term, surgical technologies. What management terms “new applications” consists of non-invasive ventilation, NHF therapy, and surgical humidification. Of these, we see the NHF devices and consumables, which are marketed under the Airvo/Optiflow label, as having the most potential reach. The benefits of NHF therapy delivered via nasal prongs include better clinical outcomes leading to a shorter length of hospital stay and lower overall treatment cost.